Write About Everything

Ishiwata, Naoko PhD1; Melby, Melissa Okay. PhD2; Mizuno, Shoichi PhD2; Watanabe, Shaw MD, DSc2

From the 1Department of Life Environments Management, Atomi University, Nakano, Niza-shi, Saitama, Japan; and 2National Institute of Health and Nutrition, Toyama, Shinjyuku-ku, Tokyo, Japan.

Acquired March 30, 2008; revised and accepted Might 27, 2008.

Financial assist: Otsuka Pharmaceutical Co Ltd, Japan, offered the complement and financial help.

Financial disclosure: None reported.

Address correspondence to: Naoko Ishiwata, PhD, Division of Life Environments Management, Atomi University, 1-9-6 Nakano, Niza-shi, Saitama 352-8501, Japan. E-mail: [email protected]

Purchase

Abstract

Targets:

Equol, a metabolite of the isoflavone daidzein, is hypothesized to play a serious position in the well being benefits of soy. We examined the effect of a new S-equol supplement on menopausal symptoms and temper states.

Design:

We conducted a randomized, double-blind, placebo-managed trial with our new equol complement for 12 weeks with 134 Japanese girls (aged 40-59 years). They were randomly assigned to a few teams: placebo (n = 44), 10 mg of equol per day (EQ-1; n = 44), and 10 mg of equol thrice per day (EQ-3; n = 46). Habitual isoflavone intake was restricted to 20 mg/d. Contributors accomplished menopausal symptom and Profile of Temper States questionnaires at baseline and postintervention. Physical examination and エクオール（及びエクオール　サプリ） blood and 24-hour urine assortment have been carried out at baseline and postintervention.

Results:

At baseline, whole menopausal symptom score various by menopausal and equol producer status (34.3% producers). A total of 127 participants (94.8%) completed the trial. No adverse effects have been reported, apart from a systemic rash in a single EQ-three lady. The anxiety scores of equol producers have been lower than these of nonproducers (P < 0.05). Significant differences between premenopausal and perimenopausal/postmenopausal symptom scores were observed for anxiety, somatic, and total scores. After the EQ-3 intervention, perimenopausal/postmenopausal equol nonproducers showed significant decreases from baseline in all menopausal symptom scores except depression (P < 0.01). Compared with placebo, the EQ-3 group showed significant decreases in depression scores (P < 0.05), as well as significant decreases in Tension-Anxiety (P < 0.05), Depression-Dejection (P < 0.05) and Fatigue (P < 0.01) and increases in Vigor (P < 0.05) of the Profile of Mood States.